New Treatment against critic Leukemia Approved In Europe

22/10/2014 - 2 minutes

Janssen’s Imbruvica (ibrutinib), the  once-daily oral Bruton’s tyrosine kinase (BTK) inhibitor, has been approved in Europe as a treatment for two blood cancers.

The drug has been ratified by the European Commission for the treatment of adult patients with relapsed or refractory mantle cell lymphoma, or chronic lymphocytic leukemia. The therapy functions block BTK, a protein that helps cancer cells to develop.

Mantle cell lymphoma (MCL) is a cancer and one of the rarest of the non-Hodgkin’s lymphomas. There are only about 15,000 patients presently in Europe. MCL is difficult to treat and seldom considered cured. Chronic lymphocytic leukaemia is the most common leukemia in adults, it is a cancer of white blood cells.

Imbruvica is indicated for people who have received at least one prior therapy, or for the first-line treatment in the presence of a specific mutation for patients unsuitable for chemo-immunotherapy.

The decision follows a positive opinion from the Committee for Medicinal Products for Human Use and will see the drug become available in these new indications in all 28 EU countries.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!